Intravenous Immunoglobulin Market: Overview
Noteworthy growth in the incidences of neurological disorders and autoimmune diseases across the globe is projected to help in the expansion of the global intravenous immunoglobulin (IVIG) market, according to a new study published by TMR. The study notes that the market will develop at 8.1% CAGR during forecast period 2018 to 2026.
Read Report Overview: https://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Over the period of past few years, there is notable growth in the older population across major parts of the world. This factor is likely to work as one of the key driver for the growth of the intravenous immunoglobulin (IVIG) market. Apart from this, the market will develop on the back of increased demand for highly dependable and adequate treatment measures, growing incidences of different neurological and hematological disorders, and surge in IVIG usage in off-label indications. In addition to this, the development of advanced technologies for production and purification techniques may play a key role in fueling demand for IVIG in the forthcoming years.
Home Care: Highly Lucrative End-User Segment Showing Avenues for Rapid Growth
The players operating in the intravenous immunoglobulin (IVIG) market are projected to gather prodigious avenues from the home care end-user segment. This growth of the market for of intravenous immunoglobulin (IVIG) is attributable to many factors including shifting patients’ preference for improved care at home, largely in many developed countries. Besides, the IVIG infusion is time consuming as the process of infusion requires a long period of time. Owing to this reason, the patients going through this process prefer the option of home care treatment. This scenario is creating prominent demand opportunities for home care end-user segment of the intravenous immunoglobulin (IVIG) market.
Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
Enterprises Focus on the Development of New and Advanced Therapies
ADMA Biologics, Inc., Shire plc, CSL Behring LLC, China Biologic Products, Inc., Kedrion S.p.A., Grifols S.A., Octapharma AG, Sanquin Plasma Products B.V., and LFB Biomedicaments S.A. are some of the key players working in the global intravenous immunoglobulin (IVIG) market. The existence of many players indicates that the market competition is highly intense. Thus to sustain in this situation, players in the market are utilizing various strategic moves.
Major enterprises in the intravenous immunoglobulin (IVIG) market are increasing their investments in the research and development activities. One of the prime motives of this tactic is the development and launch of new and advanced therapies.
Request Report Methodology: https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=1930
Asia Pacific: Prominent Region for Market Growth
Europe, North America, Latin America, Middle East & Africa, and Asia Pacific are some of the important regions for the global intravenous immunoglobulin (IVIG) market. Among all regions, Asia Pacific holds major share of the market. Some of the key reasons for this scenario include increased cases of various health issues, growth in the number of geriatric population, and increasing health care spending in the region.
The Asia Pacific intravenous immunoglobulin (IVIG) market is likely to experience sizable expansion opportunities in the forthcoming years. This growth can be attributed to many factors including presence of developing economies and considerable underserved patient population in the region. Apart from this, the regional market will gather the benefit of booming medical tourism, which is the outcome of rising government support and incorporation of different schemes to offer better patients treatment.
Ask References: https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=1930
Global Intravenous Immunoglobulin (IVIG) Market Segmentation
The segmentation of the global intravenous immunoglobulin (IVIG) market is performed on the basis of various key aspects such as end-user, indication, and region. Based on end-user, the market for intravenous immunoglobulin (IVIG) is classified into hospital, homecare, and clinic. In terms of indication, the intravenous immunoglobulin (IVIG) market is divided into idiopathic thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, myasthenia gravis, guillain-barre syndrome, Kawasaki disease, multifocal motor neuropathy (MMN), chronic lymphocytic leukemia, and hypogammaglobulinemia.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Intravenous immunoglobulin (IVIG) market (Indication - Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia; End user - Hospitals, Clinics, Home Care) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.”
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]
The new research report titled "Intravenous Immunoglobulin Market, Global Industry Analysis, and Forecast to 2027" gives a detailed analysis and future forecasts of the market.
The report highlights the significant players, including market size, share, and demand, development.
This report further covers the latest trends, technological advancements, and growth opportunities.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the intravenous immunoglobulin market include LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, KedrionBiopharma, BDI Pharma, Shire, CSL Behring.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Intravenous Immunoglobulin Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/intravenous-immunoglobulin-market/download-sampleMarket DynamicsThe global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects.
As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis.
Market research future has a half-cooked research report on Global Intravenous Immunoglobulin (IVIg) Market.
Taste the market data and market information presented through more than 64 market data tables and figures spread over 80 numbers of pages of the project report.
Avail the in-depth table of content TOC & market synopsis on “Intravenous Immunoglobulin (IVIg) Market Research Report –Global Forecast to 2023.”Market HighlightsThe global Intravenous Immunoglobulin (IVIg) market has been evaluated as moderately growing market and it is expected that the market will continue to grow similarly soon.
The market for Intravenous Immunoglobulin (IVIg) was around US$ 5910.8 million in 2016 and is expected to grow at a CAGR of 5.9% by 2023.Request Sample Copyhttps://www.marketresearchfuture.com/sample_request/3137Major Players in Intravenous Immunoglobulin (IVIg) market:There are plenty of large and small market players which operate in this market: ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.
(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others.Regional Analysis:Considering the global scenario of the market, North America was holding largest market share in global IVIg market in 2016.
Plaque psoriasis is most common type and about 80% of the cases are plaque psoriasis.
